Phaseline

Companies › WestVac Biopharma

WestVac Biopharma: clinical trials, targets and expected readouts

2 active drug programs in 8 registered trials: 5 Phase 2, 3 Phase 3; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Delamanid
Prodrug converted to reactive species that inhibits mycobacterial cell wall synthesis
–Phase 2Tuberculosis; Tuberculosis, MDR; Pulmonary Tuberculosis; Drug-resistant Tuberculosis …–
JDB0131 benzenesulfonate tablets
Mycobacterium tuberculosis ATP synthase inhibitor
–Phase 2Tuberculosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07170800JDB0131 benzenesulfonate tabletsPhase 2TuberculosisInfectious diseaseFeb 2026
NCT07170800DelamanidPhase 2TuberculosisInfectious diseaseFeb 2026
NCT03568383DelamanidPhase 3Tuberculosis, MDRInfectious diseaseNov 2026
NCT06081361DelamanidPhase 3Pulmonary TuberculosisInfectious diseaseDec 2026
NCT05766267DelamanidPhase 2Tuberculosis, PulmonaryInfectious diseaseDec 2026
NCT05556746DelamanidPhase 2Tuberculosis, PulmonaryInfectious diseaseJan 2027
NCT06649721DelamanidPhase 3Drug-resistant TuberculosisInfectious diseaseFeb 2027
NCT03828201DelamanidPhase 2Tuberculosis, Multidrug-ResistantInfectious diseaseMay 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Restorbio Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.